Travere Therapeutics Hits New 52-Week High of $49.09

Travere Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 49.09 on June 9, 2026. This achievement marks a remarkable increase from its 52-week low of USD 13.88, reflecting a substantial year-over-year performance of 568.09%. In comparison, the S&P 500 has shown a more modest gain of 22.99% during the same period. With a market capitalization of USD 2,514 million, Travere Therapeutics operates in a competitive industry characterized by innovation and rapid advancements. Despite its current loss-making status, indicated by a negative price-to-earnings ratio, the company continues to navigate the complexities of the market. The debt-to-equity ratio stands at -0.05, suggesting a unique financial structure, while the return on equity is reported at -43.77%. The stock's price-to-book ratio is 21.89, highlighting its valuation relative to its assets. This recent price movement underscores the dynamic nature of Travere Therapeutics' market presence.